Education
About Us
Working with TipRanks
Follow Us
Centogene (CNTGF)
OTHER OTC:CNTGF
CNTGF Stock Chart & Stats
$0.11
<$0.01(2.52%)
At close: 4:00 PM EST
$0.11
<$0.01(2.52%)
Day’s Range― - ―
52-Week Range$0.00 - $0.71
Previous CloseN/A
Volume282.00
Average Volume (3M)1.26K
Market Cap
$2.95M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-3.45
Next Earnings
Sep 03, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,000,137
10 Day Avg. Volume717
30 Day Avg. Volume1,260
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Centogene News
CNTGF FAQ
What was Centogene’s price range in the past 12 months?
Centogene lowest stock price was $0.00 and its highest was $0.70 in the past 12 months.
What is Centogene’s market cap?
Centogene’s market cap is $2.95M.
When is Centogene’s upcoming earnings report date?
Centogene’s upcoming earnings report date is Sep 03, 2025 which is 96 days ago.
How were Centogene’s earnings last quarter?
Currently, no data Available
Is Centogene overvalued?
According to Wall Street analysts Centogene’s price is currently Overvalued.
Does Centogene pay dividends?
Centogene does not currently pay dividends.
What is Centogene’s EPS estimate?
Centogene’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Centogene have?
Centogene has 29,000,137 shares outstanding.
What happened to Centogene’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Centogene?
Currently, no hedge funds are holding shares in CNTGF
Company Description
Centogene
Centogene (CNTGF) is a global leader in the field of rare disease diagnostics and genetic testing. The company operates within the biotechnology and life sciences sectors, providing comprehensive diagnostic solutions to healthcare providers, pharmaceutical companies, and research institutions. Centogene's core services include genetic testing, biomarker discovery, and data-driven insights, all aimed at improving patient outcomes and advancing precision medicine.
Technical Analysis
Aethlon Medical
―
Enveric Biosciences
―
Revelation Biosciences
―
Universe Pharmaceuticals
―
Azitra Inc
―
Ownership Overview
―
Insiders
0.61% Other Institutional Investors
99.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---